



Disclaimers

This presentation is for information only and shall not constitute an offer to buy, sell, issue or subscribe for, or the solicitation of an offer to buy, sell or issue, or subscribe for any securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. The information contained herein is subject to change without notice and is based on publicly available information, internally developed data and other sources. Where any opinion or belief is expressed in this presentation, it is based on the assumptions and limitations mentioned herein and is an expression of present opinion or belief only. No warranties or representations can be made as to the origin, validity, accuracy, completeness, currency or reliability of the information. CannTrust Holdings Inc. ("CannTrust") disclaims and excludes all liability (to the extent permitted by law), for losses, claims, damages, demands, costs and expenses of whatever nature arising in any way out of or in connection with the information in this presentation, its accuracy, completeness or by reason of reliance by any person on any of it.

This presentation should not be construed as legal, financial or tax advice to any individual, as each individual's circumstances are different. Investors should consult with their own professional advisors regarding their particular circumstances.

The information contained in this presentation is not directed to persons or entities resident in the United States and does not constitute an offer or solicitation by anyone in the United States or in any other jurisdiction in which such an offer or solicitation is not authorized or to any person to whom it is unlawful to make such an offer or solicitation, unless otherwise exempt from United States securities legislation.

Forward-Looking Statement

Certain information contained in this presentation constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this presentation that are not statements of historical fact may be deemed to be forward-looking statements. Forward looking statements are often identified by terms such as "may", "should", "anticipate", "expect", "potential", "believe", "intend" or the negative of these terms and similar expressions. Forward-looking statements in this presentation include, but are not limited to, statements with respect to accretive earnings, statements with respect to the funded production capacity which may not be achieved or realized within the time frames stated or at all, the anticipated size and or revenue associated with the adult consumer market in Canada and the global market for medical marijuana. Forward looking statements are based on certain assumptions regarding CannTrust, including expected growth, results of operations, performance, industry trends and growth opportunities. While CannTrust considers these assumptions to be reasonable, based on information currently available, they may prove to be incorrect. Recipients are cautioned not to place undue reliance on forward-looking statements contained herein. Forward-looking statements contained herein. Forward-looking statements also necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; future legislative and regulatory developments; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favorable terms; the early stage of the cannabis industry in Canada generally, realization of funded production estimates, income tax and regulatory matters; the ability of CannTrust to implement its business strategies; competition; currency and interest rate fluctuations; th

Recipients are cautioned that the foregoing risks are not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

Forward-looking statements contained in this presentation are expressly qualified by this cautionary statement and reflect our expectations as of the date hereof, and thus are subject to change thereafter. CannTrust disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Factors that could cause anticipated opportunities and actual results to differ materially include, but are not limited to, matters referred to above and elsewhere in CannTrust's public fillings which are, or will be, available on SEDAR.

This presentation includes certain non-IFRS performance measures including cash cost of sales, cash cost to produce, gross margin on medical cannabis, net selling price.



A low cost producer with scale

Global leadership in medical cannabis

Product leadership in recreational market

A GLOBAL OPPORTUNITY: LARGE DIVERSIFIED INDUSTRY










Annual global industry revenues of \$300B+*

Global medical market \$180B (Canada: \$3B)*



- Eight Capital Projection of Global Medical Market in Seven years estimated to be \$180B
- Recreational projection of : Global Recreational Market: BMO "What could the Global Opportunity for Cannabis look like?"

WHO WE ARE



Founded by pharmacists in 2013

- CannTrust is one of Canada's most successful and we care trusted brands in cannabis
- Standardized products that enable physicians to provide accurate dosage to patients similar to pharmaceuticals
- Rapidly building capacity and capability to expand into new categories: adult use market, over the counter, natural healthcare products, health & beauty, pet care







579
Employees
Nationwide

Top Licensed Producer

5 Best Product Awards

Top Customer Service

CANNTRUST IS LOVED BY ITS CUSTOMERS: Winner of "Licensed **Producer of** the Year" award + 6 additional awards



CANNTRUST MEDICAL CANNABIS MARKET SUCCESS Building a platform for the long term





57,000+ Canadian patients



15% Of Canadian patients



70%Of sales from Oil products



2,400+
Active physicians

OPERATING MODEL CAPABILITIES

State of the art perpetual harvest greenhouse know how (Intellectual Property)

Ability to develop proprietary patented products

Innovation & commercialization

Strong management team & culture



LEADING CLINICAL TRIALS AS LEGALIZATION OPENS UP IN NEW COUNTRIES

Be a global resource for the medical cannabis community

CURRENT STUDIES



Trial:

Canntrust CBD Oil for slowing disease progression in Amyotrophic Lateral Sclerosis (ALS) or Motor Neuron Disease (MND).

Design:

A randomized, placebo-controlled, double-blind clinical trial.



BRIGHTER WORLD



Trial:


Cannabis oil for chronic pain treatment, this is the first of its kind.

Design:

A randomized, controlled, double-blind, placebo study exceeding 300 patients.

New trials to be announced shortly!

- Accelerated medical community acceptance
- Intellectual property creation
- Patient insurance coverage



INDUSTRY GROW METHOD EVOLUTION: CANNTRUST IS LEADING THE WAY

Cost from seed to harvest Yield: 300 grams/sq. ft. annually Indoor Crops per year: 4-5 \$2.00 per gram **Facility** Percentage of top grade flower: 95% Yield: 175grams/sq. ft. annually Greenhouse \$0.95 per gram Crops Per Year: 1-2 Percentage of top grade flower: 50% **CannTrust-Niagara Facility** Yield: 250grams/sq. ft. annually Perpetual Harvest \$0.75 per gram Crops per year: 5-6

Percentage of top grade flower: 95%

Outdoor Facility

Greenhouse

Yield: 50 grams/sq. ft. annually

Crops Per Year: 1

Percentage of top grade flower: 25%

\$0.25 per gram



GREENHOUSE & OPERATIONAL CAPABILITIES

A low cost producer with scale



100,000 kg 2019+ Annual grow capacity



3,400
Milligrams of cannaboids per sq. ft.



\$0.83
Cost per Gram - current

Low Cost Producer with Scale

450,000 sq. ft. Niagara Perpetual Harvest Facility with an additional 600,000 sq. ft. greenhouse expansion in progress

- Higher yields per square foot
- Using cogeneration equipment for lower power costs and heat recovery
- Perpetual grow allows for maximum efficiency of labour
- Free energy from natural sunlight

Seed Technology Innovation

- Innovative auto flower genetics that lower capital costs
- Provides for unlimited production capacity for greenhouse and field crop both domestically and internationally
- Enables 70% reduction in growing costs
- Target cost per gram of \$0.25/ gram



MANUFACTURING AND PACKAGING

State of the art manufacturing line







10,000+/day of finished goods units for the medical and recreational market

Multihead weigher, capper and labeler technology

Hard shell vegan capsules with banding technology



ENTERED THE ADULT USE MARKET IN CANADA WITH 4 Brands and +90 SKUs













- One of the largest alcohol distributors in North America (\$5B+ annual revenue)
- Experience with provincial boards and private retailers
- Exclusive partner of CannTrust for distribution of cannabis brands

KEY PARTNERSHIPS SECURED (MORE UNDER DISCUSSION)





- #1 Alcohol distributor in Canada
- Exclusive route to market partnership with CannTrust
- Route planning, sales tools, analytics and insights



- Retail store partnership
- Preferred status & shelf space in 200+ Retail stores in 18 months






Global partnership to conduct clinical trials, and develop innovation targeting the veterinary and retail channels

Active Partnership Discussions

- Beverages
- Manufacturing
- Pharmaceutical
- Mass retail
- Over the Counter
- NHP products
- Other CPG



MANAGEMENT - DEEP KNOWLEDGE & EXPERIENCE

Poised for rapid scaling



Ian Abramowitz **Chief Financial** Officer



Peter Aceto Chief Executive Officer



Michael Camplin Production & Cultivation



Chris Lucky Supply Chain & Manufacturing



Kaivan Talachian **Professional Services Strategy & Business**



Brady Green Production & Cultivation



Bernard Yeung Development



































Cam Fletcher Production & Cultivation






Human resources



Rob Schenkel **Technology**





Jeffrey Zietlow Marketing

Dr. Ilana Platt

Innovation &

Research





Eric Paul Chairman of the Board & Cofounder



Mark Litwin Vice Chairman



Mitchell Sanders




Robert Marcovitch



Mark Dawber



Shawna Page



CANNTRUST TEAM AND CULTURE CAPABILITIES



Subject Matter Experts(10PHD's)



Every Employee is a Shareholder



We Care



Science & Innovation



Consumer Packaged Goods



Market Commercialization



Supply Chain



Rapid Scaling




Branding



International Growth





STRONG FINANCIALS SUPPORT OUR PLANS TO BE SCALABLE

Q3 2018


	Q3 2018
Revenue	\$12.6M
Adj. Gross profit*	\$9.4M
Adj. Gross Margin rate	75%
SG&A	\$8.8M
SG&A rate	70%
EBITDA	\$0.6M
EBITDA (%)	5%

Revenue Growth
105%
YoY

\$86.3M
Cash Equivalents

Patients
+61%
YoY

+387%
YoY



LONG TERM STRATEGIC PILLARS










Extend our leadership position in Canada and accelerate globally

Expand into consumer relevant product categories

First to market with product innovation

Product patents for global market leadership



ACCELERATING GROWTH IN THE CANADIAN MEDICAL CANNABIS MARKET



Providing a new way to manage chronic conditions

- Accelerate growth of our patient base
 - Patient outreach
 - Exceptional customer service
 - Standardized products and consistent supply
- Expand Health Care Practitioners (HCP) partners
 - Strategic partnerships with Cannabis Clinics
 - HCP outreach through medical education
- Develop innovative cannabis-based medicines
 - Improve efficacy and bioavailability
 - Improve compliance and quality of life
- Invest in clinical research to drive acceptance in medical community
 - Focus on chronic pain and neurological disorders

STRATEGIC INTERNATIONAL GROWTH OPPORTUNITIES

Legalization of cannabis creates a global shift

CannTrust's International Development Approach

- The perfect joint venture or partnership allows for synergies to be created between CannTrust IP and our partner's local market expertise
- Medical is the foundation to international strategy
 - International markets will legalize medical cannabis first
 - Our experience and knowledge in medical gives CannTrust credibility in accessing commercial and research partnerships
 - Allows us to have a leadership position in development of new IP
- CannTrust is also prepared to create financial alignment through equity investment







AUSTRALIA CANNATREK PARTNERSHIP BUILT FOR LONG TERM SUCCESS

CannaTrek is a cannabis company focusing on low-cost, high quality, medical production in Australia developing complete vertical integration with a similar business model.

PARTNERSHIP STRUCTURE

CannaTrek benefits:

- Leverage CannTrust's expertise in:
 - Greenhouse development & cultivation
 - Call centre, detailing HCP
- Access to intellectual property and know-how
- Import of plant materials and finished product

CannTrust benefits:

- 19.8% ownership stake in CannaTrek(ability to maintain equity stake up to and including IPO)
- ROFR on offtake for significant supply of low cost product
- Access into Asian markets due to proximity and relations with Australia




From seed to patient.

One of the first Australian cannabis companies to be awarded all medical cannabis licenses

Developing 1.7M sq.ft. of low cost (below \$0.20/gram) greenhouse in Shepparton utilizing optimal growing climate

Awaiting licensing for completed 40,000 sq.ft. low tech greenhouse with expected first harvest pre-IPO

Expected IPO mid 2019



DENMARK PARTNERSHIP BUILT FOR LONG TERM SUCCESS



PARTNERSHIP STRUCTURE

Stenocare benefits:

- Proven production & business model
- Product supplier (import and sell products)
- Help build a cultivation facility in Denmark
- Leverage IP and know-how
- Plant materials

Joint venture with Canntrust (19% ownership stake)

STENOCARE became Europe's first marijuana IPO on October 26, 2018

First Mover - Received approvals from Danish Medicines Agency

Strategic distribution agreements with hospitals and pharmacies



ADULT USE MARKET – EXPAND INTO CONSUMER RELEVANT CATEGORIES

CURRENT PRODUCT



NEW PRODUCTS





DRIVING INNOVATION THROUGH NANOTECHNOLOGY

Nanotechnology Ready Now

- A concentrated, water soluble, tasteless colorless and odorless product
- Ideal for CBD/THC-infused beverages and sublingual strips/sprays
- Patent pending process




Medical & Nutraceuticals
Products



Cannabis infused flavoured coolers / sparkling beverages



Multi-serve for 1 oz servings, designer cannabinoids, 0 calorie formats




Benefits vs. similar technologies

Higher bioavailability

for Athletic Recovery

- Lower cost to manufacture
- Faster manufacturing process
- Monodispersed (all particle sizes are same)





CANNABIS <u>PATENTS</u> ON SINGLE SERVE BEVERAGE PODS




















- Patents issued in U.S., Canada and Australia
- Patent pending in China and European Patent office
- Whole flower extract with a 99% purity with:
 - Tea
 - Coffee
 - Hot Chocolate

Ready for the edibles market in 2019!







Cap Table

CannTrust Capitalization Table	
Common Shares Outstanding	105,578,053
Warrants Outstanding	9,181,506
Stock Options Outstanding	4,548,760
Fully Diluted Shares Outstanding	119,308,319
Breakthru Beveverage Group	902,405
Cash (as of September 30, 2018)	\$86,317,593

TRST: TSX



Thank You GreyWolf *→* CannTrust **** *** GreyWolf GreyWoo GreyWolf GreyWol ♣ CannTrust XSCAPE CO CK 183 liiv -CANNABIS PACE CREAM XSCAPE XSCAPE **♦**CannTrust CannTruet CannTrust ENERGY CANNABIS INFUSED CBD + ECHINACEA CANNABIS HEUSED TEA CBD + VITAMIN C BREWBUDZ CannTru. BOARDARD & CONTINUE S 14 141 XSCAPE

Contact Information:

Investor@canntrust.ca canntrust.ca

